Progression-free survival (PFS) outcomes for previously-treated patients with advanced MCC after treatment with avelumab (anti-PD-L1) compared with PFS rates from previous chemotherapy trials (historical controls)
| Anti-neoplastic agent(s) | Median PFS, months (95% CI) | PFS rate at 12 months, % (95% CI) | Reference |
|---|---|---|---|
| Avelumab (N = 88) | 2.7 (1.4–6.9) | 30 (21–41) | [39] |
| Cowey 2017 (n = 20) | 2.1 (1.0–3.2) | 0 | [42] |
| Becker 2016 (n = 34) | 3.0 (2.6–3.1) | 0 | [43] |
| Iyer 2016 (n = 30) | 2.0 (NA [range: 0.4–11.6]) | 0* | [14] |
The most common second-line chemotherapy was topotecan. NA, not available; *based on PFS range (11–354 days) and Kaplan-Meier PFS estimates